Member Info for doggo

This excites me.

It is a very positive sign that Bank of America Merrill Lynch has joined Citibank, Credit Suisse and Julius Baer in recognizing that modifying or slowing the aging process will be tractable in the short term and worthy of attention from the wider investor community. Juvenescence’s founders have found that a portfolio approach to age modification will mitigate the typical risks associated with biotechnology companies and dramatically improve its chances of successfully bringing products to market. Currently, there are only a handful of companies taking a portfolio approach to addressing aging.

Looking to the future, we are excited by the prospect of pioneering the massive market described by Bank of America Merrill Lynch and others and are very confident in our approach to develop therapeutic agents that modify aging and increase healthy lifespan.

Ex and non holders should start to realise that the majority of LTH are sitting on a current loss with no intention of selling before they see value achieved.

No sells for 46 hours

True true

On a couple more buys

https://twitter.com/dj_papz/status/1159508580753641473?s=21

The man from Del Montre has been talking to a friend Quint

Jim is talking again by the way

I’ll give up the first time he beats me to a scoop

Save it for after 430

So far they’ve presented at Credit Suisse, are presenting at Baer and I’m summizing that they are presenting at Bank of America Merrill Lynch. High worth individuals...

Expect to see a rush from exholders who all waiting for results to confirm NAV increase.

Love news when markets are closed after a decent sell off for huge losses. Hope some of you took a haircut. Lol

That’s superb news by the way

News that slipped past me...

Google.org joins Strada Education Network and The James Irvine Foundation to back pioneering workforce development program.

“This initiative should serve as a model for innovation in workforce development across the country,” said Andrew Dunckelman of Google.org. “The Workforce ISA Fund is an important step towards a nationwide shift in the way we think about education and training to prepare for the jobs of the future.”

“Our goal is to expand access to education at a time when the shelf life of skills is shrinking, and ‘one-and-done’ learning is no longer enough to equip individuals with skills that will last throughout their careers,” said Tonio DeSorrento of Vemo Education, which is leading the design and implementation of the Workforce ISA Fund.

Investment Opportunities

Aubrey de Grey (JUV MAN)is one of a handful of specialists that have been working tirelessly within longevity research or ‘gerontology before it was even recognised as a legitimate area of science. Along with pioneers such as David Sinclair, Mike West(JUV MAN), Greg Bailey(JUV MAN), Laura Deming and others, de Grey is now actively working with an increasingly engaged group of investors at events such as the Longevity Forum in London to ensure the innovations coming from the not for profit sector feed directly into the wider commercial side of the industry.

The response has already been startling. Investment in longevity biotech start-ups has rocketed from 200 to 800 million in less than four years and is only likely to increase further as human trials continue.

The challenge, as with all nascent investment opportunities, will be separating the charlatans from the real leaders in the field.

Barclays Private Bank has reached out to a global network of experts to understand the key investment challenges and opportunities within this field. Our detailed Beyond 100 white paper and series of videos looks closely at the impact of longer, healthier lives on the global economy.

“We’ve reached an inflection point,” says Greg Bailey, CEO of Juvenescence Ltd - a drug development and artificial intelligence company focused on ageing and age-related diseases: “where our stem cell company is interacting our machine learning company and then they are both able to interact with our associated pure scientists who are working on the biology of aging to find novel therapies.”

For Bailey, this ecosystem is very important. He sees the combination of small molecule drugs, genetic engineering, stem cell research and senolytic drugs working across disciplines to create advances in lifespan: “The percentage of cells in your knee that are senescent when you have osteoarthritis, could be anywhere from 10-30%,” says Bailey.

“If we have a product that destroys 30% of the tissue in your knee, you’re not walking out of my clinic. But what if I gave you that drug and then inject pluripotent stem cells into your knee and that regenerates your knee, not with 70 year old or 60 year old cells, but one day or one week old cells? That’s what we’re excited to focus on at Juvenescence.”

Nice

Interesting link emerged this morning ....

As we know Emmac Chairman is Tom Rooke. Currently he is Finance Director of the Northern Europe Area at British American Tobacco operating in complex regulatory and commercial environments and sits on the Board of numerous operating entities as part of his current role. The business includes Pharma and Next Generation Product operations.

We also know Constellation invested $4 billion into Canopy Growth (cannabis) last year. One of the directors of Constellation is Jerry Fowden.

British American Tobacco RNS this morning announced Jerry Fowden has joined the board.

I can’t imagine a conglomerate valued in the billions wants to be sharing profits with tinpot aim company. Can you?

S-1 SEC doc for anyone interested

https://www.sec.gov/Archives/edgar/data/1766363/000119312519155034/d681105ds1.htm